ChiCTR2100048727 版本V1.0 版本创建时间2022/02/20 11:03:37 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100048727 

最近更新日期:

Date of Last Refreshed on:

2021-07-13 04:21:08 

注册时间:

Date of Registration:

2021-07-13 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

类黄酮饮食干预对癌症患者肠道菌群及应激状态的影响

Public title:

Effects of flavonoid diet intervention on intestinal flora and stress state in cancer patients

注册题目简写:

English Acronym:

研究课题的正式科学名称:

类黄酮饮食干预对癌症患者肠道菌群及应激状态的影响

Scientific title:

Effects of flavonoid diet intervention on intestinal flora and stress state in cancer patients

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李悦 

研究负责人:

康欣梅 

Applicant:

Yue Li 

Study leader:

Xinmei Kang 

申请注册联系人电话:

Applicant telephone:

19105020537

研究负责人电话:

Study leader's telephone:

13720879248

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

lylayla@stu.xmu.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

kxm791107@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国福建省厦门市翔安区翔安东路2000号

研究负责人通讯地址:

中国福建省厦门市翔安区翔安东路2000号

Applicant address:

2000 Xiang 'an East Road, Xiang 'an District, Xiamen City, Fujian Province, China

Study leader's address:

2000 Xiang 'an East Road, Xiang 'an District, Xiamen City, Fujian Province, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

厦门大学附属翔安医院肿瘤内科

Applicant's institution:

Department of Oncology, Xiang'an Hospital of Xiamen University, Xiamen University

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

XAHLL2021013

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

厦门大学附属翔安医院伦理审查会

Name of the ethic committee:

Ethics Committee of Xiang 'an Hospital of Xiamen University

伦理委员会批准日期:

Date of approved by ethic committee:

2021-07-05 00:00:00

伦理委员会联系人:

陈甜

Contact Name of the ethic committee:

Tian Chen

伦理委员会联系地址:

福建省厦门市翔安区翔安东路2000号

Contact Address of the ethic committee:

2000 Xiang 'an East Road, Xiang 'an District, Xiamen City, Fujian Province, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

厦门大学附属翔安医院

Primary sponsor:

Xiang 'an Hospital of Xiamen University

研究实施负责(组长)单位地址:

中国福建省厦门市翔安区翔安东路2000号

Primary sponsor's address:

2000 Xiang 'an East Road, Xiang 'an District, Xiamen City, Fujian Province, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

福建

市(区县):

厦门

Country:

China

Province:

Fujian

City:

Xiamen

单位(医院):

厦门大学附属翔安医院

具体地址:

翔安区翔安东路2000号

Institution
hospital:

Xiang 'an Hospital of Xiamen University

Address:

2000 Xiang'an Road East, Xiang 'an District

经费或物资来源:

厦门大学附属翔安医院康欣梅院内科研启动经费

Source(s) of funding:

Kang Xinmei's research start up funds of Xiang'an Hospital of Xiamen University

Target disease:

Advanced malignant solid tumor

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本研究旨在探索类黄酮饮食干预对癌症患者机体肠道菌群改变,机体慢性应激的影响及其相关机制。 1. 主要目的 1)探讨类黄酮饮食对患者肠道菌群的改变及其意义; 2)探讨类黄酮饮食对患者焦虑、抑郁等精神心理压力引起的慢性应激的改变。 2. 次要目的 1)探讨类黄酮饮食对患者生存质量的影响; 2)探讨类黄酮饮食对患者机体免疫能力的影响。  

Objectives of Study:

The purpose of this study is to explore the effects of flavonoid diet intervention on changes of intestinal microflora and chronic stress in cancer patients and its related mechanisms. 1. Main purpose 1) To investigate the changes and significance of flavonoid diet on intestinal flora of patients; 2) To investigate the effects of flavonoid diet on the chronic stress caused by anxiety, depression and other mental stress in patients. 2. Secondary purpose 1) To investigate the effect of flavonoid diet on the quality of life of patients; 2) To investigate the effects of flavonoid diet on the immune capacity of patients.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.有确切的病理学和CT等影像学证据,确诊为晚期恶性实体瘤的患者;
2.F&V饮食习惯低于平均每天4.4份;
3.男性或女性,年龄18岁~80岁;
4.Karnofsky评分≥60;
5.预计生存期≥3个月;
6.受试者须在试验前对本研究知情同意,并自愿签署书面的知情同意书,依从性好;
7.主要器官功能正常。

Inclusion criteria

1.Patients diagnosed as advanced malignant solid tumor with definite pathological and CT imaging evidence;
2.F&V diets are below the average of 4.4 servings per day;
3.Male or female, age 18 ~80 years old;
4.Karnofsky score ≥60;
5.Expected survival ≥3 months;
6.Subjects must give informed consent to the study before the study and voluntarily sign a written informed consent, which shows good compliance;
7.The major organs are functioning normally.

排除标准:

1)年龄<18岁或>75岁者;
2)在入组前5周内服用过抗生素;
3)在入组前和整个研究过程中使用益生菌和/或益生元补充剂和/或补充食品(≥3次/周);
4)随机分组前30天内接受其他研究药物治疗的患者;
5)入组前3个月内接受精神类药物治疗(抗抑郁药、抗焦虑药抗躁狂药等);
6)入组前14天内接受过全身使用的皮质类固醇(强的松>10mg/天或等价剂量的同类药物)或其他免疫抑制剂治疗的患者,除外以下患者:使用局部、眼部、关节腔内、鼻内和吸入型皮质类固醇治疗;短期使用皮质类固醇进行预防治疗(例如预防多西他赛、造影剂过敏);
7)认知、沟通障碍;
8)女性患者怀孕或处于哺乳期;
9)研究者认为存在可能对参与者完成研究的依从性或指标测量产生不利影响的任何其他情况,或可能对参与者造成重大风险的任何其他情况。

Exclusion criteria:

1) Age<18 or>80 years old;
2) Have taken antibiotics within 5 weeks before enrollment;
3) Use of probiotic and/or prebiotic supplements and/or supplementary foods (≥3 times per week) before enrolment and throughout the study;
4) Patients who received other study drugs within the previous 30 days were randomized;
5) Psychotropic drug therapy (antidepressants, anti-anxiety drugs, anti-manic drugs, etc.) was received within 3 months before enrollment;
6) Patients who had received systemic corticosteroids (prednisone > 10mg/ day or equivalent equivalent) or other immunosuppressive therapy within 14 days prior to enrollment, except for the following: topical, ocular, intraarticular, intranasal, and inhaled corticosteroids; Short-term use of corticosteroids for preventive treatment (e.g. to prevent docetaxel, contrast agent allergy);
7) Cognitive and communication barriers;
8) The female patient is pregnant or lactating;
9) The Investigator considers that there are any other circumstances that may adversely affect the participants' compliance with the study or measurement of indicators, or that may pose a significant risk to the participants.

研究实施时间:

Study execute time:

From 2021-07-05 00:00:00 To 2022-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-07-05 00:00:00 To 2022-09-30 00:00:00  

干预措施:

Interventions:

组别:

干预组

样本量:

30

Group:

Intervention group

Sample size:

干预措施:

高类黄酮含量果蔬饮食指导

干预措施代码:

Intervention:

High flavonoid content fruit and vegetable diet guidance

Intervention code:

组别:

对照组

样本量:

30

Group:

Control group

Sample size:

干预措施:

干预措施代码:

Intervention:

No

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

福建 

市(区县):

厦门 

Country:

China 

Province:

Fujian 

City:

Xiamen 

单位(医院):

厦门大学附属翔安医院 

单位级别:

三级甲等 

Institution
hospital:

Xiang 'an Hospital of Xiamen University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

类黄酮标志物

指标类型:

主要指标

Outcome:

Flavonoid markers

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

唾液皮质醇

指标类型:

主要指标

Outcome:

Salivary cortisol

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血液皮质醇

指标类型:

主要指标

Outcome:

Blood cortisol

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肠道菌群

指标类型:

主要指标

Outcome:

Gut microbiota

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

免疫细胞及因子

指标类型:

次要指标

Outcome:

Immune cells and cytokines

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心理健康评估问卷

指标类型:

主要指标

Outcome:

Mental Health Assessment Questionnaire

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

粪便短链脂肪酸

指标类型:

主要指标

Outcome:

Fecal short chain fatty acids

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

排便习惯及性状改变

指标类型:

主要指标

Outcome:

Changes in defecation habits and traits

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

唾液

组织:

Sample Name:

saliva

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

粪便

组织:

Sample Name:

Stool

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由研究者使用IBM? SPSS? Statistics 软件对入组患者进行编号后产生随机序列,并根据随机序列分入不同组别。

Randomization Procedure (please state who generates the random number sequence and by what method):

The IBM? SPSS? Statistics software was used to number the enrolled patients and generate a random sequence. According to the random sequence, the patients were assigned to different groups.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

试验完成后6个月内公开在百度云网盘https://pan.baidu.com/

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Share IPD on Baidu Cloud Netdisk within 6 months after the trial is completed

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

本试验采用EXCEL进行数据记录。数据录入人员应将原始资料信息准确、及时、完整、规范地录入。监查员根据源文件及时对试验采集数据进行一致性核查,确保数据录入及时、准确、规范。数据管理员根据预先制定的核查计划,对试验采集数据进行充分核查,以确保数据的正确性和完整性。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Excel was used for data recording in this experiment. Data entry personnel should accurately, timely, completely and standardly entry of the original information. According to the source files, the supervisor shall timely check the consistency of the collected test data to ensure that data entry is timely, accurate and standardized. The data manager shall fully check the collected test data according to the pre-established verification plan to ensure the correctness and integrity of the data.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2021-07-13 04:21:09